MedKoo Cat#: 561326 | Name: Nogalamycin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nogalamycin is an anthracycline antibiotic produced by soil bacteria Streptomyces nogalater. It has antitumor properties but it is also highly cardiotoxic.

Chemical Structure

Nogalamycin
Nogalamycin
CAS#1404-15-5

Theoretical Analysis

MedKoo Cat#: 561326

Name: Nogalamycin

CAS#: 1404-15-5

Chemical Formula: C39H49NO16

Exact Mass: 787.3051

Molecular Weight: 787.81

Elemental Analysis: C, 59.46; H, 6.27; N, 1.78; O, 32.49

Price and Availability

Nogalamycin, purity > 98%, is out of in stock. We will list price if it available in the future.
Related CAS #
No Data
Synonym
Nogalamycin, Nogalamycine, Nogalamycinum, Nogalomycin, Nogalamyicn, U-15167, U 15167, U15167
IUPAC/Chemical Name
Methyl 11-((6-desoxy-3-C-methyl-2,3,4-tri-O-methyl-alpha-L-mannopyranosyl)oxy)-4-dimethylamino-3,4,5,6,9,11,12,13,14,16-decahydro-3,5,8,10,13-pentahydroxy-6,13-dimethyl-9,16-dioxo-2,6-epoxy-2H-naphthaceno(1,2-b)-oxocin-14-carboxylate
InChi Key
KGTDRFCXGRULNK-OSOIFZHCSA-N
InChi Code
InChI=1S/C39H49NO16/c1-14-32(49-7)39(4,52-10)33(50-8)36(53-14)54-19-13-37(2,48)24(34(47)51-9)15-11-16-21(27(43)20(15)19)28(44)22-18(41)12-17-30(23(22)26(16)42)55-35-29(45)25(40(5)6)31(46)38(17,3)56-35/h11-12,14,19,24-25,29,31-33,35-36,41,43,45-46,48H,13H2,1-10H3/t14-,19?,24?,25?,29?,31?,32-,33-,35?,36-,37?,38?,39+/m0/s1
SMILES Code
O=C(C1C(C)(O)CC(O[C@H]2[C@@H]([C@]([C@H]([C@H](C)O2)OC)(C)OC)OC)C3=C(O)C(C(C4=C(O)C=C5C(OC6C(O)C(N(C)C)C(O)C5(C)O6)=C4C7=O)=O)=C7C=C13)OC
Appearance
Red to off-red Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Certificate of Analysis
Safety Data Sheet (SDS)

Preparing Stock Solutions

The following data is based on the product molecular weight 787.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Klymyshin D, Stephanyshyn O, Fedorenko V. [THE ROLE OF (p)ppGpp MOLECULES IN FORMATION OF "STRICT RESPONSE" IN BACTERIA AND BIOSYNTHESIS OF ANTIBIOTICS AND MORPHOLOGICAL DIFFERENTIATION IN ACTINOMYCETES]. Tsitol Genet. 2016 Mar-Apr;50(2):65-74. Review. Russian. PubMed PMID: 27281927. 2: Ghaemmaghami M, Jett JR. New agents in the treatment of small cell lung cancer. Chest. 1998 Jan;113(1 Suppl):86S-91S. Review. PubMed PMID: 9438696. 3: Andoh T. [Inhibitors of DNA topoisomerases]. Gan To Kagaku Ryoho. 1997 Sep;24(11):1526-35. Review. Japanese. PubMed PMID: 9309151. 4: Lasota WS, de Valeriola DL, Piccart MJ. Potential role of oral anthracyclines in older patients with cancer. Drugs Aging. 1994 May;4(5):392-402. Review. PubMed PMID: 8043941. 5: Ogawa M, Ariyoshi Y. [New anthracyclines]. Gan To Kagaku Ryoho. 1993 Jan;20(1):27-33. Review. Japanese. PubMed PMID: 8422185. 6: Ueoka H, Ohnoshi T, Kimura I. [New anthracycline analogues in the treatment of lung cancer]. Gan To Kagaku Ryoho. 1992 Nov;19(13):2146-9. Review. Japanese. PubMed PMID: 1332624. 7: Li LH, Krueger WC. The biochemical pharmacology of nogalamycin and its derivatives. Pharmacol Ther. 1991;51(2):239-55. Review. PubMed PMID: 1838416. 8: Muggia FM, Green MD. New anthracycline antitumor antibiotics. Crit Rev Oncol Hematol. 1991;11(1):43-64. Review. PubMed PMID: 1831987. 9: Brown TD, Burris HA, Havlin KA, O'Rourke TJ, Rodriguez GI, Wall JG, Weiss GR. New anticancer agents. Cancer Chemother Biol Response Modif. 1991;12:111-46. Review. PubMed PMID: 1718374. 10: Weiss GR, Arteaga CL, Brown TD, Craig JB, Harman GS, Havlin KA, Koeller JM, Kuhn JG, Von Hoff DD. New anticancer agents. Cancer Chemother Biol Response Modif. 1988;10:85-116. Review. PubMed PMID: 2484323. 11: Neidle S, Pearl LH, Skelly JV. DNA structure and perturbation by drug binding. Biochem J. 1987 Apr 1;243(1):1-13. Review. PubMed PMID: 3038075; PubMed Central PMCID: PMC1147807. 12: Wadler S, Fuks JZ, Wiernik PH. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds. J Clin Pharmacol. 1986 Sep-Oct;26(7):491-509. Review. PubMed PMID: 2944917. 13: Weiss RB, Sarosy G, Clagett-Carr K, Russo M, Leyland-Jones B. Anthracycline analogs: the past, present, and future. Cancer Chemother Pharmacol. 1986;18(3):185-97. Review. PubMed PMID: 2948729. 14: Young CW, Raymond V. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives. Cancer Treat Rep. 1986 Jan;70(1):51-63. Review. PubMed PMID: 2935251. 15: Strauss DG. Anthracyclines--modern tumour-inhibiting agents. Folia Microbiol (Praha). 1978;23(2):152-61. Review. PubMed PMID: 348587.